These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37272195)

  • 21. Novel Pharmacotherapy for Hypertrophic Cardiomyopathy.
    Wong TC; Martinez M
    Cardiol Clin; 2019 Feb; 37(1):113-117. PubMed ID: 30447712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.
    Spoladore R; Fragasso G; Pannone L; Slavich M; Margonato A
    Expert Opin Pharmacother; 2020 Feb; 21(2):233-242. PubMed ID: 31893930
    [No Abstract]   [Full Text] [Related]  

  • 23. A systematic review of present and future pharmaco-structural therapies for hypertrophic cardiomyopathy.
    Sawan MA; Prabakaran S; D'Souza M; Behbahani-Nejad O; Gold ME; Williams BR; Bilen O
    Clin Cardiol; 2024 Jan; 47(1):e24207. PubMed ID: 38269637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.
    Tamargo J; Tamargo M; Caballero R
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy.
    Chatur S; Hegde SM
    Curr Opin Cardiol; 2023 Sep; 38(5):424-432. PubMed ID: 37382090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug therapy of hypertrophic cardiomyopathy].
    Hartmann A; Kaltenbach M; Hopf R
    Fortschr Med; 1992 Sep; 110(27):485-8. PubMed ID: 1358773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.
    Palandri C; Santini L; Argirò A; Margara F; Doste R; Bueno-Orovio A; Olivotto I; Coppini R
    Drugs; 2022 Jun; 82(8):889-912. PubMed ID: 35696053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
    Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
    Tower-Rader A; Ramchand J; Nissen SE; Desai MY
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-modality management of hypertrophic cardiomyopathy.
    Rao SJ; Iqbal SB; Kanwal AS; Aronow WS; Naidu SS
    Hosp Pract (1995); 2023 Feb; 51(1):2-11. PubMed ID: 36598161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy.
    Liang LW; Lumish HS; Sewanan LR; Shimada YJ; Maurer MS; Weiner SD; Clerkin KJ
    J Card Fail; 2024 May; ():. PubMed ID: 38777216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics.
    Altibi A; Alani A; Zhao Y; Masri A
    Curr Cardiol Rep; 2023 Jun; 25(6):583-595. PubMed ID: 37103749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
    Scholtz S; Rudolph V; Reil JC
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options.
    Stătescu C; Enachi Ș; Ureche C; Țăpoi L; Anghel L; Șalaru D; Pleșoianu C; Bostan M; Marcu D; Ovanez Balasanian M; Sascău RA
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling].
    Coppini R; Ferrantini C; Poggesi C; Mugelli A; Olivotto I
    G Ital Cardiol (Rome); 2016 Mar; 17(3):189-96. PubMed ID: 27029877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy.
    Deb SJ; Schaff HV; Dearani JA; Nishimura RA; Ommen SR
    Ann Thorac Surg; 2004 Dec; 78(6):2118-22. PubMed ID: 15561048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
    Desai MY; Owens A; Geske JB; Wolski K; Naidu SS; Smedira NG; Cremer PC; Schaff H; McErlean E; Sewell C; Li W; Sterling L; Lampl K; Edelberg JM; Sehnert AJ; Nissen SE
    J Am Coll Cardiol; 2022 Jul; 80(2):95-108. PubMed ID: 35798455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
    Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
    Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten.
    Mathai S; Williams L
    Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.